

RECEIVED

F-32 3 2001

TECH CENTER 1600/2900

32. A method of amplifying ETF in a sample comprising contacting the sample with the nucleic acid of claim 21.

33. A method of inhibiting the expression of ETF in a sample comprising contacting the sample with the nucleic acid of claim 21.



Remarks

Applicants have added claims 20-33, which are supported throughout the specification, and particularly at page 26, line 19 to page 27, line 30, at page 36, line 30 to page 37, line 12, and at page 12, lines 14-22.

For the convenience of the Examiner, a clean copy of the pending claims (claims 1-5 and 20-33) is attached. Claims 1-5 are unchanged; claims 20-32 are added by this amendment.

If a telephone interview would be helpful in advancing the prosecution of this application, Applicants' attorney invites the Examiner to call her at the number provided below.

Respectfully submitted,

Julie K. Smith, Ph.D.
Registration No. 38,619

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Phone: (206) 389-4079
Facsimile: (206) 233-0644

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: January 3, 2001

Signed: Spencer M. Kerton